Literature DB >> 6225292

Tolerance of tetrabenazine during long-term treatment.

B O Mikkelsen.   

Abstract

Side-effects, haematological, hepatic and renal changes during long-term treatment with tetrabenazine (Nitoman) were assessed in a multicentre trial of 124 patients with various hyperkinetic syndromes. Side-effects were infrequent and usually mild. They necessitated discontinuation of therapy in 5 cases. Changes in clinico-chemical tests during 12 months on tetrabenazine were always minor, nearly always unsystematic and, on the whole, tended more towards a normalization of values than the opposite. Even recognizing the limitations inherent in a uncontrolled trial, we conclude that long-term treatment with tetrabenazine seems to be quite safe.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6225292     DOI: 10.1111/j.1600-0404.1983.tb04816.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

1.  Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study.

Authors:  Rita Miguel; Marcelo D Mendonça; Raquel Barbosa; Filipa Ladeira; Tânia Lampreia; José Vale; Paulo Bugalho
Journal:  Ther Adv Neurol Disord       Date:  2016-11-21       Impact factor: 6.570

Review 2.  Tourette's syndrome and role of tetrabenazine: review and personal experience.

Authors:  Mauro Porta; Marco Sassi; Mario Cavallazzi; Maurizio Fornari; Arianna Brambilla; Domenico Servello
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

3.  Tetrabenazine in the treatment of Huntington's disease.

Authors:  Diana Paleacu
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.